The ORR was 5% (a total of two PRs, one in a patient with a c-KIT exon 13 mutation, and one in a patient with a wild-type c-KIT), which emphasizes the concept of using these TKIs in c-KIT mutant melanomas only [71]. The gene discussed is KIT; the disease is melanoma.